FdaApplication
BLA 125057
Identifiers
- fda_app_no: BLA125057
Properties
| Property | Value |
|---|---|
| applicant_name | AbbVie Inc. |
| application_type | BLA |
| approval_date | 2002-12-31 |
Revenue by product
HUMIRA
| Period | Revenue |
|---|---|
| Q2 2026 | $756.0M |
| Q1 2026 | $688.0M |
| Q4 2025 | $1.2B |
| Q3 2025 | $993.0M |
| Q2 2025 | $1.2B |
| Q1 2025 | $1.1B |
| Q4 2024 | $1.7B |
| Q3 2024 | $2.2B |
| Q2 2024 | $2.8B |
| Q1 2024 | $2.3B |
| Q4 2023 | $3.3B |
| Q3 2023 | $3.5B |
| Q2 2023 | $4.0B |
| Q1 2023 | $3.5B |
| Q4 2022 | $5.6B |
| Q3 2022 | $5.6B |
| Q2 2022 | $5.4B |
| Q1 2022 | $4.7B |
| Q4 2021 | $5.3B |
| Q3 2021 | $5.4B |
| Q2 2021 | $5.1B |
| Q1 2021 | $4.9B |
| Q4 2020 | $5.2B |
| Q3 2020 | $5.1B |
| Q2 2020 | $4.8B |
| Q1 2020 | $4.7B |
| Q4 2019 | $4.9B |
| Q3 2019 | $4.9B |
| Q2 2019 | $4.9B |
| Q1 2019 | $4.4B |
| Q4 2018 | $4.9B |
| Q3 2018 | $5.1B |
| Q2 2018 | $5.2B |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
HUMIRA
| Period | Revenue |
|---|---|
| Q2 2026 | $756.0M |
| Q1 2026 | $688.0M |
| Q4 2025 | $1.2B |
| Q3 2025 | $993.0M |
| Q2 2025 | $1.2B |
| Q1 2025 | $1.1B |
| Q4 2024 | $1.7B |
| Q3 2024 | $2.2B |
| Q2 2024 | $2.8B |
| Q1 2024 | $2.3B |
| Q4 2023 | $3.3B |
| Q3 2023 | $3.5B |
| Q2 2023 | $4.0B |
| Q1 2023 | $3.5B |
| Q4 2022 | $5.6B |
| Q3 2022 | $5.6B |
| Q2 2022 | $5.4B |
| Q1 2022 | $4.7B |
| Q4 2021 | $5.3B |
| Q3 2021 | $5.4B |
| Q2 2021 | $5.1B |
| Q1 2021 | $4.9B |
| Q4 2020 | $5.2B |
| Q3 2020 | $5.1B |
| Q2 2020 | $4.8B |
| Q1 2020 | $4.7B |
| Q4 2019 | $4.9B |
| Q3 2019 | $4.9B |
| Q2 2019 | $4.9B |
| Q1 2019 | $4.4B |
| Q4 2018 | $4.9B |
| Q3 2018 | $5.1B |
| Q2 2018 | $5.2B |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (11)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| HUMIRA | ADALIMUMAB | 40MG/0.8ML | Injection |
| HUMIRA | ADALIMUMAB | 40MG/0.8ML | Injection |
| HUMIRA | — | 40MG/0.4ML | Injection |
| HUMIRA | — | 20MG/0.4ML | Injection |
| HUMIRA | — | 10MG/0.1ML | Injection |
| HUMIRA | — | 40MG/0.8ML | Injection |
| HUMIRA | — | 10MG/0.2ML | Injection |
| HUMIRA | — | 40MG/0.4ML | Injection |
| HUMIRA | — | 20MG/0.2ML | Injection |
| HUMIRA | — | 80MG/0.8ML | Injection |
| HUMIRA | — | 80MG/0.8ML | Injection |
11 products